Second-generation antipsychotics work primarily by blocking two types of receptors in the brain: dopamine D2 receptors and serotonin 5-HT2A receptors. This dual action is what separates them from older, first-generation antipsychotics, which only target dopamine. The added serotonin blockade, combined with a looser grip on dopamine receptors, allows these medications to treat a broader range of symptoms while causing fewer movement-related side effects.
Dopamine, Serotonin, and the Dual Blockade
The core theory behind psychosis centers on dopamine. In schizophrenia, certain dopamine pathways in the brain become overactive, producing positive symptoms like hallucinations and delusions. Both first- and second-generation antipsychotics reduce this overactivity by blocking D2 dopamine receptors. The difference lies in what else second-generation agents do.
Second-generation antipsychotics also block the 5-HT2A subtype of serotonin receptors. This matters because serotonin normally acts as a brake on dopamine release in certain brain regions. By blocking that brake in the prefrontal cortex, these drugs can actually increase dopamine activity in areas where it’s too low. This is significant because schizophrenia isn’t just about too much dopamine in one place. Dopamine activity in the cortex tends to be reduced, which contributes to negative symptoms: loss of motivation, social withdrawal, difficulty feeling pleasure, and cognitive problems. First-generation drugs, which only suppress dopamine broadly, can actually worsen these symptoms. Second-generation agents, by selectively boosting cortical dopamine through serotonin blockade, can address both sides of the equation.
The Fast Dissociation Theory
For years, the standard explanation for why second-generation antipsychotics cause fewer movement side effects was their serotonin activity. A competing hypothesis, published in the American Journal of Psychiatry, argues that the real explanation is simpler: these drugs let go of the D2 receptor faster.
Among all antipsychotics, the affinity for D2 receptors varies nearly a thousand-fold. But 99% of that variation comes down to how quickly the drug detaches from the receptor, not how quickly it binds. Second-generation agents tend to bind, do their work, and release, allowing normal dopamine signaling to resume between doses of receptor blockade. First-generation drugs latch on tightly and stay, which suppresses dopamine transmission so thoroughly that the brain’s movement-control circuits get disrupted.
This fast-off, fast-on pattern means the drug can still reduce psychotic symptoms (which require sustained dopamine overactivity) without clamping down so hard that it causes stiffness, tremors, or the involuntary movements known as tardive dyskinesia. It also helps explain why second-generation agents are less likely to raise prolactin levels, since prolactin release is controlled by dopamine in the pituitary gland.
Partial Agonists: A Third Approach
A subset of second-generation antipsychotics, including aripiprazole, brexpiprazole, and cariprazine, take an entirely different approach. Rather than simply blocking D2 receptors, they act as partial agonists. This means they can both stimulate and inhibit dopamine signaling depending on what’s already happening in that part of the brain.
When dopamine activity is too high, as in the limbic system during psychosis, these drugs act as net antagonists and dial it down. When dopamine activity is too low, as in cortical areas responsible for motivation and cognition, they provide a mild boost. This mechanism has been called “dopamine stabilization” because a single drug adjusts its effect based on the local chemical environment. The goal is to keep dopamine activity below the threshold that produces psychosis but above the level that causes movement side effects or emotional blunting.
What These Drugs Treat
Since clozapine became the first second-generation antipsychotic approved in the United States in 1989, 15 agents in this class have received FDA approval. They’re now prescribed for schizophrenia, bipolar disorder, major depressive disorder, Parkinson’s disease psychosis, irritability associated with autism, and agitation in dementia. Common names include risperidone, olanzapine, quetiapine, lurasidone, and ziprasidone, among others.
Their advantage over first-generation drugs is most apparent in the treatment of negative and cognitive symptoms of schizophrenia. While older antipsychotics are effective against hallucinations and delusions, they do little for the withdrawal, low motivation, and thinking difficulties that often cause the most disability. Second-generation agents, through their combined dopamine and serotonin effects, show meaningful improvement in these areas. A meta-analysis of randomized trials confirmed that lurasidone, for example, improved both positive and negative symptom scores on standardized scales.
Movement Side Effects
The most clinically important difference between the two generations is the risk of tardive dyskinesia, a condition involving involuntary, repetitive movements of the face, tongue, and limbs that can become permanent. A meta-analysis of comparative randomized controlled trials found that the annualized incidence of tardive dyskinesia was 6.5% with first-generation agents compared to 2.6% with second-generation agents. Put another way, the risk drops to roughly one-third. For every 20 patients switched from a first-generation to a second-generation antipsychotic, one case of tardive dyskinesia is prevented.
The risk isn’t zero, though. Second-generation antipsychotics can still cause movement problems, particularly at higher doses or with prolonged use. The reduction in risk is meaningful enough that these drugs have largely replaced first-generation agents as the standard of care.
Metabolic Side Effects
The trade-off for fewer movement problems is a different set of side effects. Second-generation antipsychotics, particularly olanzapine and clozapine, carry significant metabolic risks. These two drugs are associated with metabolic syndrome in 25% to 50% of patients. In a major clinical trial, olanzapine caused weight gain of nearly 1 kilogram per month, and over a full year, both olanzapine and clozapine led to approximately 12 kilograms of weight gain. Quetiapine and risperidone were more moderate, adding 2 to 3 kilograms over the same period.
The risks extend beyond weight. Clozapine and olanzapine are linked to the highest rates of elevated cholesterol, and the prevalence of type 2 diabetes among people taking second-generation antipsychotics ranges from 3% to 28%, depending on the specific drug. Risperidone and quetiapine fall in the moderate-risk category for diabetes. These metabolic effects likely stem from the drugs’ activity at histamine and serotonin receptors involved in appetite regulation and insulin signaling, though the exact mechanisms are still being mapped.
Prolactin Elevation Varies by Drug
Not all second-generation antipsychotics affect hormone levels equally. Prolactin, a hormone involved in breast tissue development and milk production, rises when dopamine signaling in the pituitary is suppressed. Among all antipsychotics, paliperidone and risperidone elevate prolactin the most, with risperidone raising levels by up to 41 ng/mL at higher doses. This can cause breast tenderness, menstrual changes, and sexual dysfunction.
On the other end of the spectrum, aripiprazole actually lowers prolactin at higher doses, consistent with its role as a partial dopamine agonist that mildly stimulates pituitary dopamine receptors. Brexpiprazole, cariprazine, lumateperone, and quetiapine carry negligible risk for prolactin elevation. The middle tier, including olanzapine, lurasidone, and ziprasidone, poses moderate risk that increases with dose.
Clozapine: The Most Effective, Most Monitored
Clozapine occupies a unique position in this drug class. It remains the only antipsychotic with proven superiority for treatment-resistant schizophrenia, meaning it works when other medications have failed. Its fast dissociation from D2 receptors is among the fastest of any antipsychotic, which likely contributes to its very low rate of movement side effects.
The cost of this effectiveness is a rare but serious risk of severe neutropenia, a dangerous drop in white blood cells that compromises the immune system. Until February 2025, a strict federal monitoring program required blood test results before every pharmacy dispensing. The FDA removed that mandatory program in early 2025, though it still recommends regular blood count monitoring: weekly for the first six months, every two weeks from six to twelve months, and monthly after one year. This monitoring schedule, while less restrictive than before, reflects the ongoing need for vigilance with clozapine use.